Free Trial

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Time to Buy?

Ascentage Pharma Group International logo with Medical background

Key Points

  • Ascentage Pharma Group International shares experienced a significant increase, gapping up from a previous close of $37.60 to an opening price of $41.50, representing a 10.4% rise.
  • A hedge fund, Chevy Chase Trust Holdings LLC, has acquired a new stake in the company, purchasing 5,753 shares valued at approximately $227,000 during the second quarter.
  • Ascentage Pharma is a clinical-stage biotechnology company focused on developing therapies for cancers, hepatitis B, and age-related diseases, established in May 2009 in Suzhou, China.
  • Want stock alerts on Ascentage Pharma Group International? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $37.60, but opened at $41.50. Ascentage Pharma Group International shares last traded at $41.21, with a volume of 13,722 shares changing hands.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 3.24. The stock's fifty day moving average is $37.07.

Institutional Trading of Ascentage Pharma Group International

An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Chevy Chase Trust Holdings LLC acquired a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,753 shares of the company's stock, valued at approximately $227,000.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Featured Stories

Should You Invest $1,000 in Ascentage Pharma Group International Right Now?

Before you consider Ascentage Pharma Group International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.

While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines